ALISTROL - Lower High Blood Pressure Today!


Aloeride® - Aloe Vera Capsules

New Antidepressant Developments and Approvals


New antidepressant development, until fairly recently, was at best a random, and at worst a problematic and frustrating, process. Often, medications that were developed for one thing were discovered quite accidentally to have much more important therapeutic effects for a completely different disorder. It has been well described that some of the original antipsychotics were originally developed to assist in anesthesia, and some of the original new antidepressants were originally intended to be medications for tuberculosis or psychosis. New antidepressant development was done on a "chemical" basis; that is, guesses were made as to compounds that would be safe and effective based on chemical structures of established medications. This was very much a trial-and-error process, since very little was known about how these drugs worked and very little could be measured beyond actually giving them to a patient.

New antidepressant development always has been and always will be a partnership between efficacy (ie, whether the drug is effective) and safety (ie, whether the drug can be tolerated by a patient). There were very few ways of knowing the answers to those two questions about any given compound unless you tried it, a process not without its obvious risks. It should be noted that vagus nerve stimulation for depression clearly meets the two main FDA requirements of safety and efficacy.

Medications to treat depression; mild, severe, bipolar, or treatment-resistant, make the news most frequently, and deservedly so. Their progress and approval can potentially benefit almost 8 million Americans who suffer from some form of depression. Because there seems to be more frequency now of depression that is treatment-resistant, meaning most methods of treatment (medications, psychotherapy, electroconvulsive therapy, or a combination of more than one treatment) have failed for a patient, the approval of new antidepressants from companies like Merck, Lilly, and Pfizer, are more important than ever. This is because a new class of medication for treating depression has not been developed in over a decade.

On July 18th, 2005 the FDA approved the first ever treatment long term treatment option for depression; vagus nerve stimulation. You can learn more about this remarkable treatment at http://www.VagusNerveStimulator.com There is a free electronic newsletter to keep you up-to-date.

Charles Donovan was a patient in the FDA investigational trial of vagus nerve stimulation as a treatment for chronic or recurrent treatment-resistant depression. He was implanted with the vagus nerve stimulator in April of 2001. He chronicles his journey from the grips of depression thanks to vagus nerve stimulation therapy in his book:

Out of the Black Hole: The Patient's Guide to Vagus Nerve Stimulation and Depression

The book was exhibited at the American Psychiatric Association's Annual Meeting in May. It is available on his web site and 24 hours a day/7 days a week through the toll free number 1-888-VAGUS-88. If you use discount code FDAYES(all caps), it will save you 25% off the cost of the book and you will get automatic free shipping via U.S. Postal Priority Mail.

The book is also available through Amazon.com and Barnes & Noble.com. The discount does not apply at these two sites.

He is the founder of the http://www.VagusNerveStimulator.com Web Site

MFIII-Antiaging-Clinic


Irish Take Bitter Medicine To Survive Age of Red Ink
Wall Street Journal
DUBLIN—Debt-laden Ireland is winning applause from financial markets for quickly taking the kind of harsh economic medicine that countries ...

and more »


KXJZ News

Regenerative Medicine Conference Attracts Vets, Researchers
TheHorse.com
More than 260 research scientists, veterinarians, and physicians from around the globe attended the first North American Veterinary Regenerative Medicine ...
Miracles of Science in Regenerative MedicineMyBangalore
Stem Cell Research Facility coming to UC DavisRocklin and Roseville Today
$62 million UC Davis center puts Sacramento at hub of stem cell researchSacramento Bee

all 6 news articles »


Medicine in the dark
Los Angeles Times
Michael Hochman, MD, is an assistant professor of clinical medicine at USC's Keck School of Medicine. Danny McCormick, MD, MPH, is an assistant professor of ...



BioMimetic Therapeutics Presents Promising Pre-Clinical Sports Medicine Data ...
MarketWatch (press release)
The Company's sports medicine team will present results of two pre-clinical studies demonstrating that rhPDGF-BB, in combination with tissue specific matrix ...

and more »


Medicine Shoppe, Medicap franchisees sue Cardinal Health
Bizjournals.com
When Cardinal Health Inc. renegotiated franchise agreements with pharmacies under its Medicine Shoppe and Medicap brand last year, the company said it gave ...
Franchisees sue Medicine Shoppe, Medicap, Cardinal HealthDrug Store News
Cardinal Health sued by Medicine Shoppe, Medicap pharmacy franchiseesColumbus Dispatch
Pharmacists File Class Action Against Cardinal Health, Medicine Shoppe, and ...PR Newswire (press release)
MedCity News -TMCnet -The Associated Press
all 119 news articles »


Sports medicine expert: NFL lags on concussions
Detroit Free Press
Dr. Eric Braverman, a neurologist and sports medicine expert at New York Presbyterian Hospital/Weill Cornell Medical Center, recently spoke with Free Press ...

and more »


Washington Post

Merck, Sanofi to unite animal medicine businesses
The Associated Press
... Merck & Co. and Sanofi-Aventis SA, are uniting their animal health businesses in what would be the world's largest veterinary medicine company. ...
Merck, Sanofi Join Forces on Pet MedsMarketNewsVideo.com

all 368 news articles »


ScienceBlogs (blog)

Musings on the intersection of science, medicine, and culture
ScienceBlogs (blog)
I also write twice a month for Science-Based Medicine I was pleased to see that Dr. Kaiser responded to post from earlier this week. If you'll recall, ...
Hyping A Supplement For HIVForbes (blog)

all 2 news articles »


Clinical Trial Using Proteomics Technologies for Personalized Medicine ...
GenomeWeb Daily News
15, applies technologies from Caris Life Sciences and George Mason University's Center for Applied Proteomics and Molecular Medicine to analyze diseased ...

and more »


Globe and Mail

Laughter Is the Best Medicine, And Even Americans Can Afford It
Chicago Reader (blog)
If you're hoping President Obama passes his health care reform bill, Tuesday has been a good day — and there haven't been many. First came word that when ...
Rush Limbaugh, Inadvertent Socialized Medicine FanAlterNet (blog)

all 1,216 news articles »

Google News

Hibermate home | site map

© 2009 www.elearn-university.org